Discontinued drugs in 2010: Oncology drugs

Expert Opinion on Investigational Drugs

Volumn 20, Issue 11, 2011, Pages 1479-1496

  Williams, Robert ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

Ad IFN gamma; Amsilarotene; AR 726; Aroplatin; ASP 0265; AZD 0530; Bardoxalone; BIM 23A760; CGP 47905; CP 870893; Drozitumab; Efungumab; Galiximab; GDC 0152; Golgnerminogene pradenovac; GSK 184072; IDEC 114; JNJ 26854165; KW 2449; MYC 124; Neuradiab; NRX 4204; Patupilone; PF 3814735; PF 477736; PF 4929113; PF 5208766; Resveratrol; RG 4733; RG 7419; RG 7425; RTA 401; Saracatinib; Serdemetan; SGI 1776; SRT 501; SU 14813; TAC 101; TAK 683; TAS 109; TG 1042; TNFerade

Indexed keywords

5 [(5 FLUORO 1,2 DIHYDRO 2 OXO 3H INDOL 3 YLIDENE)METHYL] N (2 HYDROXY 3 MORPHOLINOPROPYL) 2,4 DIMETHYL 1H PYRROLE 3 CARBOXAMIDE; AMSILAROTENE; ANTINEOPLASTIC AGENT; AR 726; ASP 0265; ASP 265; BARDOXOLONE; BIM 23A760; CP 870893; DROZITUMAB; EFUNGUMAB; EPOTHILONE B; GALIXIMAB; GDC 0152; GOLNERMINOGENE PRADENOVEC; KW 2449; NEURADIAB; NRX 4204; PF 3814735; PF 4814735; PF 4929113; PF 5208766; R 4733; RESVERATROL; RG 4733; RG 7419; RG 7425; RTA 401; SARACATINIB; SERDEMETAN; SGI 1776; SNX 5422; SRT 501; TAK 448; TAK 683; TAS 109; UNCLASSIFIED DRUG; VADIMEZAN; WAY 178357;

ACROMEGALY; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE KIDNEY FAILURE; ACUTE LYMPHOCYTIC LEUKEMIA; B CELL LYMPHOMA; BRAIN CANCER; BREAST CANCER; CANDIDIASIS; CARCINOID SYNDROME; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; COST; CROHN DISEASE; CRYPTOCOCCOSIS; CUSHING DISEASE; DIARRHEA; DRUG EFFICACY; DRUG INDICATION; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; ENDOMETRIOSIS; ESOPHAGUS CANCER; FINANCE; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; HYPERPROLACTINEMIA; KIDNEY CANCER; LACTIC ACIDOSIS; LEUKEMIA; LIVER CANCER; LUNG CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; MESOTHELIOMA; MITOCHONDRIAL ENCEPHALOMYOPATHY; MUCOSA INFLAMMATION; MYELODYSPLASTIC SYNDROME; MYELOMA; NAUSEA; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHODGKIN LYMPHOMA; OVARY CANCER; PANCREAS CANCER; PROSTATE CANCER; PSORIASIS; QT PROLONGATION; REVIEW; SARCOMA; SOLID TUMOR; VOMITING;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; PRODUCT RECALLS AND WITHDRAWALS; RESEARCH;

EID: 80054002069     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2011.623697     Document Type: Review

References (14)

1. The long view: PharmaR&Dproductivity-when the cures fail, it makes sense to check the diagnosis. Bernstein Research report; 2010
2. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3(11):711-15
3. Reichert JM, Wenger JB. Development trends for new cancer therapeutics and vaccines. Drug Discov Today 2007;13(1/2):30-7
4. Arrowsmith J. Phase III and submission failures: 2007-2010. Nat Rev Drug Discov 2011;10(2):1
5. Available from: http://www.inpharm.com/news/148299/150211/rdproductivity- worse-previously-reported
6. Available from: http://www.inpharm.com/news/101223/2010-pharma-yearreview
7. Desdouits S, Delaport L, Parnis S. Roadmap for success in oncology. Scrip Exec Brief 2008;1(3):1-11
8. From pipeline to market. R&D Dir Exec Brief 2010;16(6):12
9. Trusheim MR, Berndt ER, Douglas FL. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov 2007;6(4):287-93 (Pubitemid 46505879)
10. Carden CP, Sarker D, Postel-Vinay S, et al. Can molecular biomarker-based patient selection in phase I trials accelerate anti-cancer drug development? Drug Discov Today 2009;15(3/4):88-97
11. Druker BJ, Talpaz M, Restra DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344(14):1031-7 (Pubitemid 32267972)
12. Fong PC, Yap TA, Boss DS, et al. Poly(ADP-ribose) polymerase inhibition: Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010;28:2512-19
13. Kwak EL, Bang Y-J, Camidge DR, et al. Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. N Engl J Med 2010;363:1693-703
14. Chapman PB, Hauschild A, Robert C, et al. Improved survival with Vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16